Praxis Precision Medicines, Inc. (PRAX)
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Praxis Precision Medicines, Inc.
- 1:15Reverse splitNov 29, 202315 shares → 1
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Revenue | $0 | $8.55M | $2.45M | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | 249.5% | - | - | - | - | - | - |
| Cost of Revenue | $140K | $152.41M | $86.77M | $154.44M | $0 | $0 | $679K | $1K |
| Gross Profit | -$140K | -$143.86M | -$84.32M | -$154.44M | $0 | $0 | -$679K | -$1K |
| Gross Margin | - | -1682.0% | -3445.8% | - | - | - | - | - |
| Research and Development | $267.12M | $152.41M | $86.77M | $155.04M | $120.26M | $44.98M | $29.56M | $18.82M |
| Selling, General, and Administrative | $59.08M | $56.3M | $42.05M | $59.55M | $47.08M | $16.99M | $6.23M | $3.9M |
| Other | $0 | -$152.41M | -$86.77M | -$154.04M | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $326.06M | $56.3M | $42.05M | $60.55M | $167.33M | $61.97M | $35.79M | $22.72M |
| Operating Income (EBIT) | -$326.2M | -$200.16M | -$126.37M | -$214.99M | -$167.33M | -$61.97M | -$35.79M | -$22.72M |
| Operating Margin | - | -2340.3% | -5164.4% | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $127K |
| Interest Income | $22.93M | $17.35M | $0 | $0 | $0 | $140K | $193K | $92K |
| Other Income (Expense) | $22.93M | $17.35M | $3.1M | $957K | $271K | $140K | $193K | -$3.68M |
| Income Before Tax (EBT) | -$303.27M | -$182.82M | -$123.28M | -$214.03M | -$167.06M | -$61.83M | -$35.6M | -$26.4M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | -$8K | -$84K | $133K |
| Net Income | -$303.27M | -$182.82M | -$123.28M | -$214.03M | -$167.06M | -$61.82M | -$35.51M | -$26.54M |
| Net Income Margin | - | -2137.5% | -5037.9% | - | - | - | - | - |
| Supplementary Data | ||||||||
| EPS | -13.48 | -10.21 | -18.69 | -69.33 | -58.96 | -103.61 | -348.24 | -306.73 |
| Diluted EPS | -13.48 | -10.21 | -18.69 | -69.33 | -58.96 | -103.61 | -348.24 | -306.73 |
| Weighted Average OS | 22.50M | 17.91M | 6.59M | 3.07M | 2.83M | 596,677 | 101,975 | 86,509 |
| EBITDA | -$303.13M | -$182.46M | -$122.84M | -$213.57M | -$166.88M | -$61.92M | -$34.92M | -$26.27M |
| EBITDA Margin | - | -2133.3% | -5020.2% | - | - | - | - | - |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and Cash Equivalents | $357.33M | $215.37M | $81.3M | $61.62M | $138.7M | $296.61M | $44.81M | $17.95M |
| Short-Term Investments | $242M | $177.19M | $0 | $38.87M | $137.21M | $0 | $0 | $0 |
| Cash and Short-Term Investments | $599.33M | $392.57M | $81.3M | $100.49M | $275.91M | $296.61M | $44.81M | $17.95M |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $11.58M | $11.8M | $3.58M | $0 | $0 | $0 | $0 | $0 |
| Total Current Assets | $610.91M | $404.37M | $84.88M | $110.84M | $287.41M | $302.33M | $45.5M | $19.13M |
| Long-Term Assets | ||||||||
| Property, Plant & Equipment Net | $239K | $1.36M | $2.65M | $3.87M | $4.87M | $836K | $1.58M | $103K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $76.96M | $0 | $0 | $0 | $0 | $0 | $600K |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $326.76M | $416K | $416K | $416K | $472K | $15K | $620K | $0 |
| Total Long-Term Assets | $327M | $78.74M | $3.07M | $4.29M | $5.34M | $851K | $2.2M | $703K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $937.91M | $483.11M | $87.95M | $115.13M | $292.75M | $303.18M | $47.69M | $19.83M |
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $24.63M | $12.53M | $5.82M | $14.67M | $10.78M | $4.09M | $2.67M | $3.39M |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $1.39M | $2.82M | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $18.71M | $9.37M | $3.7M | $2.8M | $7.18M | $0 | $0 | $1.02M |
| Total Current Liabilities | $59.77M | $37.55M | $15.75M | $34.34M | $38.43M | $15.72M | $6.82M | $5.14M |
| Long-Term Liabilities | ||||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $1.16M | $2.18M | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2K |
| Total Long-Term Liabilities | $0 | $110K | $2.53M | $4.68M | $3.5M | $0 | $763K | $2K |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $59.77M | $37.66M | $18.28M | $39.02M | $41.94M | $15.72M | $7.58M | $5.15M |
| Stockholders' Equity | ||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $121.12M | $55.72M |
| Common Stock | $15K | $14K | $13K | $5K | $5K | $4K | $1K | $1K |
| Retained Earnings | -$1.14B | -$836.74M | -$653.92M | -$530.64M | -$316.62M | -$149.55M | -$81.01M | -$41.37M |
| Comprehensive Income & Other | $563K | $654K | $0 | -$173K | -$176K | $0 | $0 | -$1K |
| Other Stockholders' Equity | $2.02B | $1.28B | $723.58M | $606.75M | $567.42M | $437.01M | $121.12M | $56.05M |
| Total Equity | $878.14M | $445.45M | $69.67M | $76.11M | $250.81M | $287.46M | $40.11M | $14.68M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $937.91M | $483.11M | $87.95M | $115.13M | $292.75M | $303.18M | $47.69M | $19.83M |
| Supplementary Data | ||||||||
| Total Debt | $110K | $1.37M | $2.5M | $3.5M | $4.31M | $763K | $1.46M | $0 |
| Net Debt | -$357.22M | -$214M | -$78.81M | -$58.12M | -$134.39M | -$295.85M | -$43.36M | -$17.95M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Operating Activities | ||||||||
| Net Income | -$303.27M | -$182.82M | -$123.28M | -$214.03M | -$167.06M | -$61.82M | -$35.51M | -$26.54M |
| Depreciation & Amortization | $140K | $358K | $432K | $419K | $182K | $50K | $679K | $1K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $2.09M | $0 | $0 | $3.65M |
| Stock-Based Compensation | $33.94M | $41.36M | $24.86M | $28.59M | $22.69M | $5.21M | $0 | $579K |
| Changes in Working Capital: | ||||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $12.1M | $6.71M | -$8.86M | $3.89M | $7.27M | $960K | -$837K | $1.67M |
| Other Working Capital | $10.58M | $4.21M | -$4.17M | -$5.67M | $8.87M | $2.28M | $2.21M | -$208K |
| Total Working Capital Change | $22.68M | $10.92M | -$13.03M | -$1.78M | $16.13M | $3.24M | $1.38M | $1.46M |
| Other Non-Cash Items | -$2.56M | -$1.58M | -$121K | $1.75M | $1.41M | $696K | $668K | $127K |
| Net Cash from Operating | -$249.07M | -$131.76M | -$111.14M | -$185.04M | -$124.55M | -$52.62M | -$32.79M | -$20.72M |
| Investing Activities | ||||||||
| Capital Expenditures | -$56K | $0 | -$50K | -$444K | -$1.05M | $0 | -$103K | -$63K |
| Acquisitions | $0 | $0 | $0 | -$97.33M | $139.47M | $0 | $0 | $0 |
| Purchases of Investments | -$623.81M | -$371.52M | $0 | -$83.02M | -$164.17M | $0 | $0 | $0 |
| Sales of Investments | $312.72M | $123.03M | $39M | $180.35M | $24.7M | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $97.33M | -$139.47M | $0 | $0 | $0 |
| Net Cash from Investing | -$311.15M | -$248.49M | $38.95M | $96.89M | -$140.52M | $0 | -$103K | -$63K |
| Financing Activities | ||||||||
| Debt Repaid | - | - | - | - | $763K | - | - | -$1M |
| Common Stock Issuance | $704.26M | $512M | $91.59M | $9.56M | $105.71M | $334.42M | $60.39M | $36.8M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | -$30M | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$2.09M | $2.33M | $279K | $904K | $2.63M | $88K | $0 | $0 |
| Net Cash from Financing | $702.17M | $514.32M | $91.87M | $10.46M | $107.59M | $304.42M | $59.76M | $37.8M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $141.96M | $134.07M | $19.68M | -$77.69M | -$157.49M | $251.79M | $26.86M | $17.02M |
| Supplementary Data | ||||||||
| Operating Cash Flow | -$249.07M | -$131.76M | -$111.14M | -$185.04M | -$124.55M | -$52.62M | -$32.79M | -$20.72M |
| Capital Expenditure | -$56K | $0 | -$50K | -$444K | -$1.05M | $0 | -$103K | -$63K |
| Free Cash Flow | -$249.12M | -$131.76M | -$111.19M | -$185.49M | -$125.6M | -$52.62M | -$32.89M | -$20.78M |
| Cash at Beginning | $215.79M | $81.72M | $62.03M | $139.72M | $297.21M | $45.41M | $17.95M | $1.53M |
| Cash at End | $357.75M | $215.79M | $81.72M | $62.03M | $139.72M | $297.21M | $44.81M | $18.55M |